Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2020 - 12 - 07 save search
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
Published: 2020-12-07 (Crawled : 22:00) - globenewswire.com
AGIO | News | $29.43 1.38% 1.36% 550K
|
Health Technology
|
| O: -9.8%
H: 0.0%
C: -6.89%
disease phase 3 phase 1 phase 2
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
Published: 2020-12-07 (Crawled : 14:01) - globenewswire.com
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
|
| O: 0.88%
H: 2.25%
C: 1.03%
phase 3 trial potential psoriasis plague
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
Published: 2020-12-07 (Crawled : 13:05) - globenewswire.com
KROS | $59.08 -0.32% -0.32% 300K
|
Health Technology
|
| O: -0.36%
H: 2.91%
C: -2.8%
results trial phase 3 phase 1 phase 2 preclinical pre-clinical
Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis
Published: 2020-12-07 (Crawled : 13:05) - globenewswire.com
DARE | $0.299 5.77% 5.45% 970K
|
Health Technology
|
| O: -6.0%
H: 2.84%
C: -5.67%
positive results phase 3 trial topline
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Published: 2020-12-07 (Crawled : 13:02) - globenewswire.com
ONCT | News | $8.79 -1.79% -1.82% 2.8K
|
Health Technology
|
| O: 48.5%
H: 23.29%
C: 0.76%
phase 3 phase 1 phase 2
Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 1.53%
H: 0.03%
C: -1.35%
biotech phase 3
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3819 -0.55% -1.05% 200K
|
Health Technology
|
| O: 0.0%
H: 2.47%
C: -19.01%
phase 3 phase 1 phase 2 t-cell
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -2.91%
H: 0.0%
C: -7.0%
trial phase 3 phase 1 phase 2 clinical hold
Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia
Published: 2020-12-07 (Crawled : 12:02) - globenewswire.com
TNXP | $0.1549 -2.82% -2.91% 1.4M
|
Health Technology
|
| O: 61.9%
H: 0.0%
C: -31.37%
positive results phase 3 fibromyalgia
HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability
Published: 2020-12-07 (Crawled : 11:01) - globenewswire.com
HOOK | $0.7695 0.92% 0.91% 170K
|
Health Technology
|
| O: 2.13%
H: 8.6%
C: 6.34%
cancer therapy treatment phase 3 phase 1 phase 2
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.